Tectonic Therapeutic Shares Hit 52-Week High After Positive Trial Data
Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein.
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...
TECX stock reached a new 52-week high this week, with shares trading at an impressive $53.6. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from ...
The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback